Pharmaceuticals, Biotechnology and Life Sciences
CTI BioPharma has enrolled 150 patients with myelofibrosis previously treated with ruxolitinibto be tested on pacritinib in the second phase, testing three dosing schedules over 24 weeks.
CTI BioPharma is expecting $10 million milestone in February, 2018 from Teva, related to a milestone for U.S. Food and…
CTI BioPharma has completed enrollment in the Phase 3 PIX306 trial of PIXUVRI (pixantrone).
European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for CTI BioPharma’s pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia.
CTI BioPharma has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for Trisenox (arsenic trioxide).
CTI BioPharma has announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the “Offering”).
CTI BioPharma has reported net loss of $19.8 million for the first quarter of 2017. The loss is decrease compared to the profit of $3.3 million for the same period in 2016.
Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but…
CTI BioPharma has reported neto loss of $6.4 million for the fourth quarter 2016. Net loss has decreased comparing the same period last year when the company reported net loss of $28.8 million. As for the full year, the company has reported net loss of $52.0 million, which is also decrease comparing last years loss of $122.6 million.
CTI BioPharma has appointed Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors